Literature DB >> 9360502

Phenotype: genotype relationships in growth hormone insensitivity syndrome.

K A Woods1, F Dastot, M A Preece, A J Clark, M C Postel-Vinay, P G Chatelain, M B Ranke, R G Rosenfeld, S Amselem, M O Savage.   

Abstract

GH insensitivity syndrome (GHIS) is associated with many different mutations of the GH receptor (GHR) gene. We examined the phenotypic and biochemical features in 82 GHIS patients from 23 countries, each fulfilling diagnostic criteria of GHIS. There were 45 males and 37 females [mean age, 8.25 yr; mean height, -6.09 SD score, and mean insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), -7.99 SD score]. Sixty-three were GH-binding protein (GHBP) negative; 19 were GHBP positive (> 10% binding). The mean height in GHBP-negative subjects was -6.5 SD score, and that in GHBP-positive patients was -4.9 SD score (P = < 0.001). Clinical and biochemical heterogeneity was demonstrated by the wide range of height (-2.2 to -10.4 SD score) and IGFBP-3 (-1.4 to -14.7 SD score) values, which were positively correlated (r2 = 0.45; P = < 0.001). This contrasted with the lack of correlation between mean parental height SD score and height SD score (r2 = 0.01). Fifteen different GH receptor gene mutations were identified in 27 patients. All had homozygous defects, except 1 who had a compound heterozygous defect. The mutations were 5 nonsense, 2 frame shift, 4 splice, 4 missense, and 1 compound heterozygote. There was no relationship between mutation type or exon of the GHR gene involved and height or IGFBP-3 SD score. In conclusion, GHIS is associated with wide variation in the severity of clinical and biochemical phenotypes. This variation cannot clearly be accounted for by defects in the GHR gene. Other genetic and/or environmental factors must, therefore, contribute to phenotype in GHIS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360502     DOI: 10.1210/jcem.82.11.4389

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  Growth hormone insensitivity: a widening diagnosis.

Authors:  R Bjarnason; M O Savage
Journal:  Arch Dis Child       Date:  1999-11       Impact factor: 3.791

2.  Pseudoexon activation as a novel mechanism for disease resulting in atypical growth-hormone insensitivity.

Authors:  L A Metherell; S A Akker; P B Munroe; S J Rose; M Caulfield; M O Savage; S L Chew; A J Clark
Journal:  Am J Hum Genet       Date:  2001-07-20       Impact factor: 11.025

Review 3.  Insulin-like growth factor (IGF)-I gene deletion.

Authors:  Cecilia Camacho-Hübner; Katie A Woods; Adrian J L Clark; Martin O Savage
Journal:  Rev Endocr Metab Disord       Date:  2002-12       Impact factor: 6.514

Review 4.  Growth hormone and IGF-1.

Authors:  Roberto Salvatori
Journal:  Rev Endocr Metab Disord       Date:  2004-03       Impact factor: 6.514

5.  Pregnancy-associated plasma protein (PAPP)-A expressed in the mammary gland controls epithelial cell proliferation and differentiation.

Authors:  Makoto Nakasato; Hitoshi Kohsaka; Tetsuya Mizutani; Gen Watanabe; Kazuyoshi Taya; Kentaro Nagaoka
Journal:  Endocrine       Date:  2012-08-17       Impact factor: 3.633

Review 6.  Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action.

Authors:  Helen L Storr; Sumana Chatterjee; Louise A Metherell; Corinne Foley; Ron G Rosenfeld; Philippe F Backeljauw; Andrew Dauber; Martin O Savage; Vivian Hwa
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

7.  Final height in a patient with Laron syndrome after long-term therapy with rhlGF-I and short-term therapy with LHRH-analogue and oxandrolone during puberty.

Authors:  S Zucchini; E Scarano; L Baldazzi; L Mazzanti; P Pirazzoli; E Cacciari
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

8.  Growth hormone receptor gene mutations in two Italian patients with Laron Syndrome.

Authors:  L Fassone; G Corneli; S Bellone; C Camacho-Hübner; G Aimaretti; M Cappa; G Ubertini; G Bona
Journal:  J Endocrinol Invest       Date:  2007-05       Impact factor: 4.256

9.  Atypical X-linked SCID phenotype associated with growth hormone hyporesponsiveness.

Authors:  M V Ursini; L Gaetaniello; R Ambrosio; E Matrecano; A J Apicella; M C Salerno; C Pignata
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

Review 10.  The continuum between GH deficiency and GH insensitivity in children.

Authors:  Martin O Savage; Helen L Storr; Philippe F Backeljauw
Journal:  Rev Endocr Metab Disord       Date:  2020-10-06       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.